Alzheimer's Disease (AD)MOIPADNCT06924359
Multimodal Ophthalmic Imaging and Plasma Biomarkers for the Early Detection of Alzheimer's Disease
An observational study of Alzheimer's Disease (AD), run by Peking University First Hospital at 1 site in China.
Trial summary
With the accelerating global aging population, dementia has become a pressing worldwide issue. This project aims to identify specific plasma biomarkers and ocular indicators for the early detection of Alzheimer's disease (AD). Read more about this study
- Who is it for?
- Ages 50 years and older
- Conditions the study is for
- Alzheimer's Disease (AD)
- What is being tested?
- Multimodal Ophthalmic Imaging and plasma biomarker
- How many people
- 200 participants
- Where
- 1 siteChina
- Study dates
- 19 Mar 2025to 31 Aug 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 years and older
- All sexes
- Adult, Older adult
Study population: AD, MCI, SCD and CN
Who may be able to join
- Male or female participants aged ≥ 50 years;
- Participants diagnosed with Alzheimer's Disease (AD), mild cognitive decline (MCI), subjective cognitive decline (SCD), or cognitively normal (CN);
- Signed informed consent form
Who cannot join
- Presence of other neurological disorders and systemic diseases that may cause cognitive impairment;
- Inability to cooperate with cognitive assessments;
- Refusal to undergo blood sampling.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Peking University First Hospital
Beijing
Yong an Prof.Sun, 83572371, sya@bjmu.edu.cn
About this study
With the accelerating global aging population, dementia has become a pressing worldwide issue. This project aims to identify specific plasma biomarkers and ocular indicators for the early detection of Alzheimer's disease (AD).
- Conditions
- Alzheimer's Disease (AD)
- Being tested
- Multimodal Ophthalmic Imaging and plasma biomarker
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Multimodal Ophthalmic Imaging and plasma biomarkerDiagnostic test
Multimodal Ophthalmic Imaging and plasma biomarkers (Aβ42/40, p-tau181, p-tau217, NfL and GFAP）.
| Study group | Role | What they receive |
|---|---|---|
| Different stages of Alzheimer's disease | Not described Receives: Diagnostic Test: Multimodal Ophthalmic Imaging and plasma biomarker |
What is being measured
The primary outcome is the main question the study is designed to answer.
Quantitative differences of core multimodal ophthalmic imaging parameters (including structural and functional ocular imaging indices) across study groups
Measured: Baseline
Secondary outcomes (1)
Concentration difference of plasma biomarkers (Aβ42/40, p - tau181, p - tau217, NfL and GFAP） among groups
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Apr 2025
- Study start19 Mar 2025
- Primary completion31 Aug 2027 (estimated)
- Study completion31 Aug 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Alzheimer's Disease (AD)Studies of the same condition, open and under way.
- More trials run by Peking University First HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Peking University First Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06924359
- Sponsor's protocol ID
- AD-BIOPR-001
- Acronym
- MOIPAD
- Status last verified
- Apr 2026
- First submitted
- 6 Apr 2025
- Last updated
- 29 Sep 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Multimodal Ophthalmic Imaging and Plasma Biomarkers for the Early Detection of Alzheimer's Disease
- ClinicalTrials.gov ID
- NCT06924359
- Acronym / sponsor ID
- MOIPAD / AD-BIOPR-001
- Conditions
- Alzheimer's Disease (AD)
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Peking University First HospitalUniversity, hospital or other
- Study start
- 19 Mar 2025 (actual)
- Primary completion
- 31 Aug 2027 (estimated)
- Study completion
- 31 Aug 2027 (estimated)
- First posted
- 11 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
With the accelerating global aging population, dementia has become a pressing worldwide issue. This project aims to identify specific plasma biomarkers and ocular indicators for the early detection of Alzheimer's disease (AD).
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Different stages of Alzheimer's disease | – | Diagnostic Test: Multimodal Ophthalmic Imaging and plasma biomarker |
Who may qualify
- Ages
- 50 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- AD, MCI, SCD and CN
Key inclusion criteria (3 listed)
- Male or female participants aged ≥ 50 years;
- Participants diagnosed with Alzheimer's Disease (AD), mild cognitive decline (MCI), subjective cognitive decline (SCD), or cognitively normal (CN);
- Signed informed consent form
Key exclusion criteria (3 listed)
- Presence of other neurological disorders and systemic diseases that may cause cognitive impairment;
- Inability to cooperate with cognitive assessments;
- Refusal to undergo blood sampling.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Multimodal Ophthalmic Imaging and plasma biomarkerMultimodal Ophthalmic Imaging and plasma biomarkers (Aβ42/40, p-tau181, p-tau217, NfL and GFAP）. | Diagnostic test | Different stages of Alzheimer's disease |
Primary outcome
Quantitative differences of core multimodal ophthalmic imaging parameters (including structural and functional ocular imaging indices) across study groups
Time frame: Baseline
1 secondary outcome
Concentration difference of plasma biomarkers (Aβ42/40, p - tau181, p - tau217, NfL and GFAP） among groups
Time frame: Baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Alzheimer's Disease (AD)
Active, not recruitingPhase 1/2
VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease
Alzheimer's Disease (AD)
RecruitingPhase 1
DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau
Alzheimer Disease, Alzheimer Disease (AD)
RecruitingPhase 1/2
Large-coil Parietal Repetitive Transcranial Magnetic Stimulation (rTMS) for Alzheimer Disease (AD)
Alzheimer&Amp;Amp;#39;s Disease, Alzheimer Disease
RecruitingObservational study
Development of Measures to Screen for Financial Hardship in Alzheimer's Disease and Dementia
Financial Hardship, Alzheimer's Disease (AD)
RecruitingPhase 3
A Clinical Study Evaluating the Diagnostic Performance and Safety of PET for the Deposition of Aβ Plaques in the Brain of Participants With Normal Cognitive Function, MCI and AD Using [18F]Fluorbetazine Injection
Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Alzheimer's Disease (AD), run by Peking University First Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 29 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Quantitative differences of core multimodal ophthalmic imaging parameters (including structural and functional ocular imaging indices) across study groups (time frame: Baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Sep 2026; AzTrials last refreshed its copy on 7 Nov 2026.